MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53

BACKGROUND: Malignant pleural mesothelioma (MPM) is a highly aggressive tumour that is first-line treated with a combination of cisplatin and pemetrexed. Until now, predictive and prognostic biomarkers are lacking, making it a non-tailored therapy regimen with unknown outcome. P53 is frequently inac...

Descripción completa

Detalles Bibliográficos
Autores principales: Walter, R F H, Mairinger, F D, Ting, S, Vollbrecht, C, Mairinger, T, Theegarten, D, Christoph, D C, Schmid, K W, Wohlschlaeger, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453955/
https://www.ncbi.nlm.nih.gov/pubmed/25668009
http://dx.doi.org/10.1038/bjc.2015.27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453955/
https://www.ncbi.nlm.nih.gov/pubmed/25668009
http://dx.doi.org/10.1038/bjc.2015.27

Ejemplares similares